ADAURA Demonstrates OS Benefit with Adjuvant Osimertinib in Resectable EGFRm NSCLC

Data Supporting IO Before Surgery in Resectable NSCLC Grows

Majority of NSCLC Patients from Low Socio-Economic Areas in England Do Not Receive Novel Anti-Cancer Therapies

Commentary: Global Initiatives to Reduce Cancer Incidence, Mortality Must Tackle Tobacco

From the Editors: Defining Resectability of Non-Small Cell Lung Cancer in 2023

Tumor Treating Fields May Provide Additional Treatment Option for mNSCLC Following Progression